These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 20020827)

  • 1. Mucosal treatments for herpes simplex virus: insights on targeted immunoprophylaxis and therapy.
    McGowin CL; Pyles RB
    Future Microbiol; 2010 Jan; 5(1):15-22. PubMed ID: 20020827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization with a replication-defective herpes simplex virus 2 mutant reduces herpes simplex virus 1 infection and prevents ocular disease.
    van Lint AL; Torres-Lopez E; Knipe DM
    Virology; 2007 Nov; 368(2):227-31. PubMed ID: 17915278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attenuated Herpes Simplex Virus 1 (HSV-1) Expressing a Mutant Form of ICP6 Stimulates a Strong Immune Response That Protects Mice against HSV-1-Induced Corneal Disease.
    Davido DJ; Tu EM; Wang H; Korom M; Gazquez Casals A; Reddy PJ; Mostafa HH; Combs B; Haenchen SD; Morrison LA
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29950407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Role for Interleukin-17 in Enhancing Type 1 Helper T Cell Immunity in the Female Genital Tract following Mucosal Herpes Simplex Virus 2 Vaccination.
    Bagri P; Anipindi VC; Nguyen PV; Vitali D; Stämpfli MR; Kaushic C
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28956763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Herpes simplex virus-2 in the genital mucosa: insights into the mucosal host response and vaccine development.
    Lee AJ; Ashkar AA
    Curr Opin Infect Dis; 2012 Feb; 25(1):92-9. PubMed ID: 22143115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Herpes Simplex Virus (HSV)-2 Single-Cycle Candidate Vaccine Deleted in Glycoprotein D Protects Male Mice From Lethal Skin Challenge With Clinical Isolates of HSV-1 and HSV-2.
    Burn C; Ramsey N; Garforth SJ; Almo S; Jacobs WR; Herold BC
    J Infect Dis; 2018 Feb; 217(5):754-758. PubMed ID: 29216362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocular herpes simplex: changing epidemiology, emerging disease patterns, and the potential of vaccine prevention and therapy.
    Pepose JS; Keadle TL; Morrison LA
    Am J Ophthalmol; 2006 Mar; 141(3):547-557. PubMed ID: 16490506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic and therapeutic modulation of innate and adaptive immunity against mucosal infection of herpes simplex virus.
    Uyangaa E; Patil AM; Eo SK
    Immune Netw; 2014 Aug; 14(4):187-200. PubMed ID: 25177251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CXCL10/CXCR3-Dependent Mobilization of Herpes Simplex Virus-Specific CD8
    Srivastava R; Khan AA; Chilukuri S; Syed SA; Tran TT; Furness J; Bahraoui E; BenMohamed L
    J Virol; 2017 Jul; 91(14):. PubMed ID: 28468883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunologic approach to herpes simplex virus.
    Whitley RJ; Miller RL
    Viral Immunol; 2001; 14(2):111-8. PubMed ID: 11398806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intramuscular vaccination of mice with the human herpes simplex virus type-1(HSV-1) VC2 vaccine, but not its parental strain HSV-1(F) confers full protection against lethal ocular HSV-1 (McKrae) pathogenesis.
    Naidu SK; Nabi R; Cheemarla NR; Stanfield BA; Rider PJ; Jambunathan N; Chouljenko VN; Carter R; Del Piero F; Langohr I; Kousoulas KG
    PLoS One; 2020; 15(2):e0228252. PubMed ID: 32027675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic immunization with a mixture of herpes simplex virus 1 glycoprotein D-derived “asymptomatic” human CD8+ T-cell epitopes decreases spontaneous ocular shedding in latently infected HLA transgenic rabbits: association with low frequency of local PD-1+ TIM-3+ CD8+ exhausted T cells.
    Khan AA; Srivastava R; Chentoufi AA; Geertsema R; Thai NT; Dasgupta G; Osorio N; Kalantari M; Nesburn AB; Wechsler SL; BenMohamed L
    J Virol; 2015 Jul; 89(13):6619-32. PubMed ID: 25878105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mathematical Modeling Predicts that Increased HSV-2 Shedding in HIV-1 Infected Persons Is Due to Poor Immunologic Control in Ganglia and Genital Mucosa.
    Schiffer JT; Swan DA; Magaret A; Schacker TW; Wald A; Corey L
    PLoS One; 2016; 11(6):e0155124. PubMed ID: 27285483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal application of plasmid-encoded IL-15 sustains a highly protective anti-Herpes simplex virus immunity.
    Toka FN; Rouse BT
    J Leukoc Biol; 2005 Jul; 78(1):178-86. PubMed ID: 15817700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Herpes. Vaccines for HSV.
    Stanberry LR
    Dermatol Clin; 1998 Oct; 16(4):811-6, xiv. PubMed ID: 9891686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Neonatal Fc Receptor and Complement Fixation Facilitate Prophylactic Vaccine-Mediated Humoral Protection against Viral Infection in the Ocular Mucosa.
    Royer DJ; Carr MM; Gurung HR; Halford WP; Carr DJJ
    J Immunol; 2017 Sep; 199(5):1898-1911. PubMed ID: 28760885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice.
    Augustinova H; Hoeller D; Yao F
    J Virol; 2004 Jun; 78(11):5756-65. PubMed ID: 15140973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccine.
    Kuo T; Wang C; Badakhshan T; Chilukuri S; BenMohamed L
    Vaccine; 2014 Nov; 32(50):6733-45. PubMed ID: 25446827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization.
    Kuklin N; Daheshia M; Karem K; Manickan E; Rouse BT
    J Virol; 1997 Apr; 71(4):3138-45. PubMed ID: 9060677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.